# EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

> **NCT00338000** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 292 (actual)

## Conditions studied

- Chronic Renal Failure

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00338000
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2011-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338000, "EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00338000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*